Sorry, you need to enable JavaScript to visit this website.

White paper | Embedding your drug strategy within a solid foundation for success

September 2019, General CDMO

Demand for drugs and therapeutics is growing thanks to the globalization of pharmaceutical-based medicine. Manufacturing new drugs and getting them to market faster, more economically and safely demands development strategies and business models that support successful outcomes for both investors and patients.

Outsourcing has become an increasingly attractive business model for pharma as companies seek partners who can deliver comprehensive end-to-end drug substance and drug product development. It has prompted contract manufacturing organizations (CMOs) to consolidate and expand to create the more comprehensive contract development and manufacturing organization (CDMO). Since then, the CDMO model has evolved and a new class of CDMO has emerged; the embedded CDMO

In this whitepaper, we look at the broad set of trends influencing pharmaceutical development and manufacturing strategy today, and how these drivers are influencing new business models with outsourced partners. We highlight the inherent value proposition of embedded CDMOs, and how this business model is helping to optimize drug substance and drug product development and commercial manufacture.

You can download the full whitepaper by completing the form below.

1 Start 2 Complete

Download white paper

Service of interest (select only one)*

Send me news and updates
We would like to send you information which Pfizer CentreOne believes may be of value to you and relevant to your work. If you would like to receive such information, please tick the box below.

By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Pfizer’s processing of your personal data, including its transfer internationally and to third parties, in accordance with the
Pfizer Privacy Policy and Pfizer website terms of use.